A detailed history of Braidwell LP transactions in Cullinan Oncology, Inc. stock. As of the latest transaction made, Braidwell LP holds 1,176,173 shares of CGEM stock, worth $14.4 Million. This represents 0.56% of its overall portfolio holdings.

Number of Shares
1,176,173
Previous 176,173 567.62%
Holding current value
$14.4 Million
Previous $3.07 Billion 540.83%
% of portfolio
0.56%
Previous 0.1%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$16.03 - $20.86 $16 Million - $20.9 Million
1,000,000 Added 567.62%
1,176,173 $19.7 Billion
Q2 2024

Aug 14, 2024

SELL
$15.63 - $29.35 $16.6 Million - $31.2 Million
-1,064,692 Reduced 85.8%
176,173 $3.07 Billion
Q4 2023

Feb 14, 2024

SELL
$7.89 - $10.23 $5.27 Million - $6.83 Million
-668,000 Reduced 34.99%
1,240,865 $12.6 Billion
Q2 2023

Aug 14, 2023

BUY
$8.8 - $13.4 $16.8 Million - $25.6 Million
1,908,865 New
1,908,865 $20.5 Billion

Others Institutions Holding CGEM

About Cullinan Oncology, Inc.


  • Ticker CGEM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,612,200
  • Market Cap $560M
  • Description
  • Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with ...
More about CGEM
Track This Portfolio

Track Braidwell LP Portfolio

Follow Braidwell LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Braidwell LP, based on Form 13F filings with the SEC.

News

Stay updated on Braidwell LP with notifications on news.